학술논문
Risk factors for long coronavirus disease 2019 (long COVID) among healthcare personnel, Brazil, 2020-2022.
Document Type
Academic Journal
Author
Marra AR; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Department of Internal Medicine, University of Iowa, Iowa City, Iowa, United States.; Sampaio VS; Instituto Todos Pela Saúde, São Paulo, São Paulo, Brazil.; Ozahata MC; Instituto Todos Pela Saúde, São Paulo, São Paulo, Brazil.; Lopes R; Instituto Todos Pela Saúde, São Paulo, São Paulo, Brazil.; Brito AF; Instituto Todos Pela Saúde, São Paulo, São Paulo, Brazil.; Bragatte M; Instituto Todos Pela Saúde, São Paulo, São Paulo, Brazil.; Kalil J; Instituto Todos Pela Saúde, São Paulo, São Paulo, Brazil.; Miraglia JL; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Malheiro DT; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Guozhang Y; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Teich VD; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Victor EDS; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Pinho JRR; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Cypriano A; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Vieira LW; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Polonio M; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; de Oliveira SM; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Ricardo VCV; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Maezato AM; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Callado GY; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Schettino GPP; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; de Oliveira KG; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Santana RAF; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Malta FM; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Amgarten D; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Boechat AL; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.; Kobayashi T; Department of Internal Medicine, University of Iowa, Iowa City, Iowa, United States.; Perencevich E; Department of Internal Medicine, University of Iowa, Iowa City, Iowa, United States.; Edmond MB; West Virginia University School of Medicine, Morgantown, West Virginia, United States.; Rizzo LV; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.
Source
Publisher: Cambridge University Press Country of Publication: United States NLM ID: 8804099 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-6834 (Electronic) Linking ISSN: 0899823X NLM ISO Abbreviation: Infect Control Hosp Epidemiol Subsets: MEDLINE
Subject
Language
English
Abstract
Objective: To determine risk factors for the development of long coronavirus disease 2019 (COVID-19) in healthcare personnel (HCP).
Methods: We conducted a case-control study among HCP who had confirmed symptomatic COVID-19 working in a Brazilian healthcare system between March 1, 2020, and July 15, 2022. Cases were defined as those having long COVID according to the Centers for Disease Control and Prevention definition. Controls were defined as HCP who had documented COVID-19 but did not develop long COVID. Multiple logistic regression was used to assess the association between exposure variables and long COVID during 180 days of follow-up.
Results: Of 7,051 HCP diagnosed with COVID-19, 1,933 (27.4%) who developed long COVID were compared to 5,118 (72.6%) who did not. The majority of those with long COVID (51.8%) had 3 or more symptoms. Factors associated with the development of long COVID were female sex (OR, 1.21; 95% CI, 1.05-1.39), age (OR, 1.01; 95% CI, 1.00-1.02), and 2 or more SARS-CoV-2 infections (OR, 1.27; 95% CI, 1.07-1.50). Those infected with the SARS-CoV-2 δ (delta) variant (OR, 0.30; 95% CI, 0.17-0.50) or the SARS-CoV-2 o (omicron) variant (OR, 0.49; 95% CI, 0.30-0.78), and those receiving 4 COVID-19 vaccine doses prior to infection (OR, 0.05; 95% CI, 0.01-0.19) were significantly less likely to develop long COVID.
Conclusions: Long COVID can be prevalent among HCP. Acquiring >1 SARS-CoV-2 infection was a major risk factor for long COVID, while maintenance of immunity via vaccination was highly protective.
Methods: We conducted a case-control study among HCP who had confirmed symptomatic COVID-19 working in a Brazilian healthcare system between March 1, 2020, and July 15, 2022. Cases were defined as those having long COVID according to the Centers for Disease Control and Prevention definition. Controls were defined as HCP who had documented COVID-19 but did not develop long COVID. Multiple logistic regression was used to assess the association between exposure variables and long COVID during 180 days of follow-up.
Results: Of 7,051 HCP diagnosed with COVID-19, 1,933 (27.4%) who developed long COVID were compared to 5,118 (72.6%) who did not. The majority of those with long COVID (51.8%) had 3 or more symptoms. Factors associated with the development of long COVID were female sex (OR, 1.21; 95% CI, 1.05-1.39), age (OR, 1.01; 95% CI, 1.00-1.02), and 2 or more SARS-CoV-2 infections (OR, 1.27; 95% CI, 1.07-1.50). Those infected with the SARS-CoV-2 δ (delta) variant (OR, 0.30; 95% CI, 0.17-0.50) or the SARS-CoV-2 o (omicron) variant (OR, 0.49; 95% CI, 0.30-0.78), and those receiving 4 COVID-19 vaccine doses prior to infection (OR, 0.05; 95% CI, 0.01-0.19) were significantly less likely to develop long COVID.
Conclusions: Long COVID can be prevalent among HCP. Acquiring >1 SARS-CoV-2 infection was a major risk factor for long COVID, while maintenance of immunity via vaccination was highly protective.